/AMRN
AMRN Stock - Amarin Corporation plc
Healthcare|BiotechnologyNASDAQ
$13.80-0.22%
$0.03 (-0.22%) • Dec 19
37
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.36
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.91
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-84.3%upside
Target: $2.17
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AMRN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$13.66 – $13.94
TARGET (TP)$2.17
STOP LOSS$12.70
RISK/REWARD1:-10.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.71
52W High$20.90
52W Low$7.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $228.61M | $306.91M | $369.19M | $583.19M | $614.06M |
| Gross Profit | $81.38M | $165.54M | $242.48M | $461.86M | $482.62M |
| Gross Margin | 35.6% | 53.9% | 65.7% | 79.2% | 78.6% |
| Operating Income | $-91,797,000 | $-67,588,000 | $-105,869,000 | $10.50M | $-19,655,000 |
| Net Income | $-82,183,000 | $-59,112,000 | $-105,803,000 | $7.73M | $-18,000,000 |
| Net Margin | -35.9% | -19.3% | -28.7% | 1.3% | -2.9% |
| EPS | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 |
Company Overview
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
33%
Hold / Neutral
2
67%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish2 Neutral/Bearish
Price Targets
$3
Average Target
↓ 81.9% Downside
Now
$1
Low
$3
Average
$3
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 20th 2023 | JP Morgan | Resumed | Underweight | - |
| October 25th 2023 | Jefferies | Downgrade | Hold | $1← $3 |
| January 6th 2023 | Jefferies | Upgrade | Buy | $3← $1.3 |
| May 6th 2022 | JP Morgan | Downgrade | Underweight | - |
| May 5th 2022 | SVB Leerink | Downgrade | Market Perform | $3← $10 |
| May 5th 2022 | H.C. Wainwright | Downgrade | Neutral | $3← $10 |
| May 4th 2022 | Northland Capital | Downgrade | Market Perform | - |
Earnings History & Surprises
AMRNBeat Rate
63%
Last 19 quarters
Avg Surprise
+131.8%
EPS vs Estimate
Beats / Misses
12/6
1 met exactly
Latest EPS
$0.01
Q4 2025
EPS Surprise History
Q1 24
-66.7%
$-0.01vs$-0.01
Q2 24
+75.0%
$-0.20vs$-0.80
Q3 24
+100.0%
$0.20vs$0.10
Q4 24
0.0%
$-1.00vs$-1.00
Q1 25
-100.0%
$-2.40vs$-1.20
Q2 25
+96.4%
$-0.04vs$-1.12
Q3 25
+95.5%
$-0.03vs$-0.66
Q4 25
-87.5%
$0.01vs$0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 11, 2026 | $-0.08 | — | — | — |
Q4 2025 | Oct 29, 2025 | $0.08 | $0.01 | -87.5% | ✗ MISS |
Q3 2025 | Jul 30, 2025 | $-0.66 | $-0.03 | +95.5% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-1.12 | $-0.04 | +96.4% | ✓ BEAT |
Q1 2025 | Mar 12, 2025 | $-1.20 | $-2.40 | -100.0% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $-1.00 | $-1.00 | 0.0% | = MET |
Q3 2024 | Jul 31, 2024 | $0.10 | $0.20 | +100.0% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $-0.80 | $-0.20 | +75.0% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.01 | $-0.01 | -66.7% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.04 | $-0.05 | -11.1% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $-0.40 | $0.40 | +200.0% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.20 | $0.40 | +300.0% | ✓ BEAT |
Q1 2023 | Mar 1, 2023 | $0.20 | $0.40 | +100.0% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $-0.40 | $0.40 | +200.0% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-1.40 | $-3.60 | -157.1% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.40 | $-1.20 | -200.0% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $0.60 | $1.20 | +100.0% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.20 | $0.60 | +400.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-1.00 | $0.60 | +160.0% | ✓ BEAT |
Q2 2021 | Apr 29, 2021 | $-0.05 | $0.60 | +1300.0% | ✓ BEAT |
Latest News
Reported Earlier, Amarin Presents New REDUCE-IT Aspirin Analysis At AHA 2025 Showing VASCEPA VAZKEPA Icosapent Ethyl Reduced Cardiovascular Events In High-Risk Patients
📈 PositiveBenzinga•Nov 10, 2025, 07:40 AM
Amarin To Present New Data Highlighting VASCEPA's Cardiovascular Benefits And EPA's Anti-Inflammatory, Antioxidant Mechanisms At AHA 2025
📈 PositiveBenzinga•Nov 3, 2025, 01:41 PM
Amarin shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Oct 29, 2025, 06:22 PM
Amarin Corp Q3 2025 Adj per ADS $0.19 Up From $(1.00) YoY, Sales $49.670M Beat $43.099M Estimate
📈 PositiveBenzinga•Oct 29, 2025, 11:17 AM
Watching Amarin; Shares Move Higher; Hearing Zacks Surprise Trader Newsletter Mentions Stock As A Buy
📈 PositiveBenzinga•Oct 24, 2025, 03:57 PM
HLS Therapeutics And Amarin To Present IPE And EPA Mechanistic Effects At Canadian Cardiovascular Congress 2025
➖ NeutralBenzinga•Oct 14, 2025, 12:48 PM
Amarin To Present Icosapent Ethyl, Eicosapentaenoic Acid Data At Canadian Cardiovascular Congress
➖ NeutralBenzinga•Oct 14, 2025, 12:06 PM
Reported Saturday, Amarin's REDUCE-IT Analyses Show Icosapent Ethyl Cuts Hospitalizations By 9% and Lowers Cardiovascular Risk In High-Risk Patients
📈 PositiveBenzinga•Sep 2, 2025, 07:49 AM
Reported Sunday, Amarin Presents Mechanistic Insights Into EPA's Cardiovascular Protection Through Lipoprotein(a) Oxidation Inhibition And NLRP3 Inflammasome Pathway Modulation
📈 PositiveBenzinga•Sep 2, 2025, 07:42 AM
Amarin To Present New Data On Icosapent Ethyl's Cardioprotective Effects At ESC 2025, Highlighting Inflammation And Oxidation Mechanisms
📈 PositiveBenzinga•Aug 25, 2025, 12:10 PM
Amarin inks licensing deal with Recordati for lead drug Vazkepa
📈 PositiveSeeking Alpha•Jun 24, 2025, 11:40 AM
Frequently Asked Questions about AMRN
What is AMRN's current stock price?
Amarin Corporation plc (AMRN) is currently trading at $13.80 per share. The stock has moved -0.22% today.
What is the analyst price target for AMRN?
The average analyst price target for AMRN is $2.17, based on 1 analyst.
What sector is Amarin Corporation plc in?
Amarin Corporation plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AMRN's market cap?
Amarin Corporation plc has a market capitalization of $0.29 billion, making it a small-cap company.
Does AMRN pay dividends?
No, Amarin Corporation plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALT
Altimmune, Inc.
$3.90
Mkt Cap: $0.3B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
CLLS
Cellectis S.A.
$4.37
Mkt Cap: $0.4B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
ENGN
enGene Holdings Inc.
$8.69
Mkt Cap: $0.4B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
LYEL
Lyell Immunopharma, Inc.
$33.33
Mkt Cap: $0.7B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
Explore stocks similar to AMRN for comparison